Landmark Research Study is Launched to Assess Impact of Personal Genet...(e chances of negative health impact. Thi...),Health

Date:10/9/2008

e chances of negative health impact. This information will be available to participants on Navigenics' secure Web site. Each participant will be able to enter and store clinical and lifestyle information in an individual Microsoft HealthVault(TM) account, allowing the participant to manage his or her personal health information in one location and share it, as desired, with health care providers or others they trust to help make more informed health care decisions.

Lifestyle changes will be tracked via participants' self-reported health assessment questionnaires, including a baseline assessment and subsequent self-reported assessments at three- and 12-month intervals after receiving gene scan results. Researchers will also ask participants to conduct periodic health surveys over the next 20 years to assess their behaviors longitudinally. A complete database of genomic and clinical information will be assembled at the Scripps Genomic Medicine program.

"We stand upon the threshold of a fundamental paradigm shift from reactive to predictive and preventive medicine," said Vance Vanier, M.D., chief medical officer of Navigenics. "Modern genomic tools are instrumental in this shift, and studies that help inform physicians about the most responsible, ethical and effective ways to help people use this information to have impact on their health are crucial. Our partnership with Scripps Health represents our shared commitment to advancing the field of preventive genomic medicine."

A number of safeguards will be in place to protect the privacy of participants' genetic information. Traditional identifying information for participants' saliva samples and self-reported health assessment questionnaires will be de-identified, encoded, encrypted and kept in a secure database.

"This project represents the largest single opportunity to date for modern genetics to move outside the laboratory and directly to consumers," said Kevin King, president of Affymetri
'/>"/>

SOURCE Scripps Translational Science Institute Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years
2. Established Safety Profile of Spiriva Confirmed by 30 Rigorously Controlled Clinical Trials and the Landmark Trial UPLIFT
3. Landmark HIV/AIDS Publication Launches at International AIDS Society Conference in Mexico City
4. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
5. TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial
6. Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
7. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
8. Hospital Launches Landmark Emergency Medicine Project
9. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
10. Viatronix V3D-Colon Utilized in Another Landmark Study
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression